image credit: Adobe Stock

Cell therapy developer closes funding round to support diabetes program

September 21, 2023

Like many biotechnology companies, Seraxis has an ambitious aim.

The company wants to transform the lives of millions of diabetics who must take insulin every day to control their blood sugar levels. Its approach: use a stem cell line generated from human pancreas to produce groups of cells known as organoids that can replicate the work of an organ.

Specifically, Seraxis is focusing on the production of insulin to control glucose levels. The bitoech says its cells are as potent as ones normally found in a healthy pancreas and have been able to reverse diabetes in rats and mice.

Read More on Biopharma Dive